Effect of dalcetrapib on non-cholesterol sterol markers of cholesterol absorption in patients with familial hypoalphalipoproteinaemia or familial combined hyperlipidaemia.

Trial Profile

Effect of dalcetrapib on non-cholesterol sterol markers of cholesterol absorption in patients with familial hypoalphalipoproteinaemia or familial combined hyperlipidaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2012

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Hyperlipoproteinaemia type IIb; Tangier disease
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2012 New trial record
    • 29 Aug 2012 Results presented at the Annual Congress of the European Society of Cardiology 2012 (ESC Congress 2012).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top